1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission by the external assessment group and submissions from stakeholders.

Eptinezumab is recommended as an option for the prevention of migraine in adults, only if they have four or more migraine days a month at least three preventive drug treatments have failed.

Read NICE technology appraisal guidance